8
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Green Renal Replacement Therapy: Caring for the Environment

      Submit here before July 31, 2024

      About Blood Purification: 3.0 Impact Factor I 5.6 CiteScore I 0.83 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Early Cyst Growth Is Associated with the Increased Nuclear Expression of Cyclin D1/Rb Protein in an Autosomal-Recessive Polycystic Kidney Disease Rat Model

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background: In this study we hypothesised that proliferation, and the increased expression of G<sub>1</sub>-phase cyclins (D1, E) and phosphorylated retinoblastoma protein (p-Rb) is restricted to the early period of synchronized cyst growth in autosomal-recessive polycystic kidney disease (ARPKD). Methods: Lewis polycystic kidney disease (lpk) rats (model of ARPKD; postnatal weeks 1, 3, 6, 12 and 24; n = 6 each) as well as human juvenile cystic renal disease tissue (n = 2) were examined. Results: Between weeks 1 and 3, the percentage cyst area increased 6-fold in lpk rats, followed by a more progressive rise (1.5-fold increase) until week 24. The number of Ki-67-, cyclin D1- and p-Rb-positive cells increased in lpk rats and peaked at week 3, declining thereafter. By serial sections, cysts co-expressed Ki-67, cyclin D1 and p-Rb. The expression of cyclin E was variable, and peaked at week 24. In human tissue, small cysts had a higher expression of p-Rb. Conclusion: Proliferation and the increased nuclear expression of cyclin D1 and p-Rb coincide with the early phase of cyst growth in rats and humans, suggesting that there might be a therapeutic window in which cyclin-dependent kinase inhibitors are most effective in preventing kidney enlargement in ARPKD.

          Related collections

          Most cited references23

          • Record: found
          • Abstract: not found
          • Article: not found

          Clinical practice. Autosomal dominant polycystic kidney disease.

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Polycystic kidney disease.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              PKD1 induces p21(waf1) and regulation of the cell cycle via direct activation of the JAK-STAT signaling pathway in a process requiring PKD2.

              Autosomal dominant polycystic kidney disease is characterized by cyst formation in the kidney and other organs and results from mutations of PKD1 or PKD2. Previous studies suggest that their gene products have an important role in growth regulation. We now show that expression of polycystin-1 activates the JAK-STAT pathway, thereby upregulating p21(waf1) and inducing cell cycle arrest in G0/G1. This process requires polycystin-2, a channel protein, as an essential cofactor. Mutations that disrupt polycystin-1/2 binding prevent activation of the pathway. Mouse embryos lacking Pkd1 have defective STAT1 phosphorylation and p21(waf1) induction. These results suggest that one function of the polycystin-1/2 complex is to regulate the JAK/STAT pathway and explain how mutations of either gene can result in dysregulated growth.
                Bookmark

                Author and article information

                Journal
                NEE
                Nephron Exp Nephrol
                10.1159/issn.1660-2129
                Cardiorenal Medicine
                S. Karger AG
                1660-2129
                2011
                April 2011
                02 October 2010
                : 117
                : 4
                : e93-e103
                Affiliations
                aCentre for Transplant and Renal Research, Westmead Millennium Institute, Sydney Medical School – Western, The University of Sydney, and bChildren’s Hospital at Westmead, and cAustralian School of Advanced Medicine, Macquarie University, Sydney, N.S.W., and dMurdoch University, Perth, W.A., Australia
                Author notes
                *Dr. G. Rangan, Centre for Transplant and Renal Research, Level 2, Clinical Sciences Block, Westmead Hospital, Westmead, Sydney, N.S.W. 2145 (Australia), Tel. +61 2 9845 6962, Fax +61 2 9633 9351, E-Mail g.rangan@wmi.usyd.edu.au
                Article
                320149 Nephron Exp Nephrol 2011;117:e93–e103
                10.1159/000320149
                20924203
                9b5e7121-ac41-461b-8d9c-011a45d5b8b1
                © 2010 S. Karger AG, Basel

                Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                History
                : 22 August 2009
                : 11 May 2010
                Page count
                Figures: 7, Tables: 2, References: 32, Pages: 11
                Categories
                Original Paper

                Cardiovascular Medicine,Nephrology
                Proliferation,Polycystic kidney disease,Cyclin
                Cardiovascular Medicine, Nephrology
                Proliferation, Polycystic kidney disease, Cyclin

                Comments

                Comment on this article